logo
Plus   Neg
Share
Email

Evotec Reaches Licensing And Master Service Agreement With Kazia On Oncology

Evotec SE (EVTCY.PK,EVOTF.PK) said Monday that it reached a licensing and master service agreement with Kazia Therapeutics Limited (KZIA).

As per the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec's oncology project EVT801.

EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec's partnership with Sanofi.

Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia.

Kazia will be responsible for any subsequent clinical evaluation and commercialisation of EVT801.

Evotec said it receives a small upfront payment as well as further payments for continued support progressing EVT801 into the clinic and beyond.

In addition, Evotec noted that it is eligible to receive clinical and commercial milestones of more than 300 million euros as well as tiered high single-digit royalties on the net sales of EVT801, which will be shared with Sanofi, Evotec's partner for the discovery and early development of EVT801.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
Follow RTT